세계의 철결핍성 빈혈 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료 유형별, 치료 분야별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Iron Deficiency Anemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type, By Therapy Areas, By End User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,385,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,805,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,352,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계 철결핍성 빈혈(IDA) 시장은 2024년 51억 4,000만 달러로 평가되었고, 예측 기간 동안 연평균 6.68% 성장하여 2030년에는 75억 9,000만 달러에 이를 것으로 예상됩니다.

IDA 시장은 전 세계적으로 다양한 연령대와 인구 집단에서 철결핍성 빈혈이 광범위하게 퍼져 있는 만큼 그 복잡성과 중요성이 증가함에 따라 광범위한 헬스케어 전망의 주요 부문으로 정의되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	51억 4,000만 달러
시장 규모 : 2030년	75억 9,000만 달러
CAGR : 2025-2030년	6.68%
급성장 부문	경구 철분 요법
최대 시장	북미

이 시장에는 IDA의 다면적 특성을 해결하기 위해 설계된 다양한 진단 솔루션, 치료법, 지지 요법 제품이 포함되며, IDA의 잠재적 건강 영향과 함께 IDA에 대한 인식이 높아짐에 따라 시장 성장의 주요 요인으로 작용하고 있습니다. 전 세계 의료 시스템이 발전하고 의료 서비스에 대한 접근성이 향상됨에 따라 조기 검진 및 진단율이 높아지면서 혁신적인 치료 옵션에 대한 수요가 증가하고 있습니다. 이에 대응하기 위해 제약회사와 의료 서비스 제공업체들은 진단 능력과 치료적 개입을 개선하기 위해 연구개발에 많은 투자를 하고 있습니다.

시장 성장 촉진요인

세계적으로 철분 결핍성 빈혈의 유병률 증가

주요 시장 이슈

경제적 격차와 의료 접근성 제한

이러한 과제를 극복하기 위해선 표적화된 정책적 개입, 보건의료 재정의 확대, 모든 인구 집단에서 저렴한 진단 및 치료제에 대한 공평한 접근이 필요합니다.

주요 시장 동향

치료 옵션의 혁신과 다양화

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 철결핍성 빈혈 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 유형별(경구 철분 요법, 비경구 철분 요법, 적혈구 수혈, 기타)
  • 치료 영역별(산부인과, 종양학, 울혈성 심부전(CHF), 염증성 장질환, 신장, 기타)
  • 최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 치료 유형별
  • 치료 영역별
  • 최종사용자별
  • 지역별

제5장 아시아태평양 철결핍성 빈혈 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 유형별
  • 치료 영역별
  • 최종사용자별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽 철결핍성 빈혈 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미 철결핍성 빈혈 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
  • 치료 유형
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미 철결핍성 빈혈 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카 철결핍성 빈혈 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 철결핍성 빈혈 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Daiichi Sankyo Company
• Novartis AG
• Rockwell Medical Inc
• Iron4u Aps
• AbbVie Inc
• Sanofi
• Disc Medicine Inc
• Pfizer Inc
• Akebia Therapeutics
• Keros Therapeutics Inc

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Iron deficiency anemia (IDA) market was valued at USD 5.14 billion in 2024 and is projected to reach USD 7.59 billion by 2030, growing at a CAGR of 6.68% during the forecast period. As a key segment within the broader healthcare landscape, the IDA market is defined by its complexity and growing significance, given the widespread prevalence of iron deficiency anemia across diverse age groups and populations globally.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.14 Billion
Market Size 2030	USD 7.59 Billion
CAGR 2025-2030	6.68%
Fastest Growing Segment	Oral Iron Therapy
Largest Market	North America

This market encompasses a broad spectrum of diagnostic solutions, therapeutic treatments, and supportive care products designed to address the multifaceted nature of IDA. Increased awareness surrounding the condition, along with its potential health consequences, is a major catalyst driving market growth. As global healthcare systems evolve and access to medical services improves, early screening and diagnosis rates are rising-resulting in greater demand for innovative treatment options. In response, pharmaceutical companies and healthcare providers are significantly investing in research and development to advance diagnostic capabilities and therapeutic interventions.

Key Market Drivers

Increasing Global Prevalence of Iron Deficiency Anemia

The escalating prevalence of IDA is one of the most significant growth drivers for the global market. Iron deficiency anemia continues to represent a major global health challenge, impacting individuals across all demographics.

Shifts in dietary habits are a key contributor. Modern diets often lack sufficient iron-rich foods, such as red meats and leafy greens, and are increasingly reliant on processed or nutrient-deficient alternatives. The growing adoption of vegetarian and vegan diets, while beneficial for various reasons, may lack heme iron-a form more readily absorbed by the body-further heightening the risk of deficiency. This has fueled demand for iron supplements, fortified foods, and other nutritional solutions.

Additionally, the rising incidence of chronic health conditions has increased vulnerability to IDA. Gastrointestinal disorders such as inflammatory bowel disease and celiac disease can inhibit iron absorption, while chronic inflammation can limit iron availability for red blood cell production. As these underlying health issues become more widespread, the need for effective IDA diagnostics and treatments continues to grow.

Key Market Challenges

Economic Inequality and Limited Access to Healthcare

Despite being a global concern, iron deficiency anemia disproportionately affects individuals in low-income and underserved regions due to economic and healthcare disparities. These disparities present considerable obstacles to diagnosis, treatment, and overall disease management.

In many developing countries, access to basic medical services remains limited. Regular health screenings and affordable diagnostic testing are often unavailable, resulting in delayed or missed diagnoses. Even when symptoms are recognized, financial constraints frequently prevent individuals from seeking care or purchasing prescribed treatments.

The affordability and consistent availability of iron supplements-a cornerstone of IDA management-pose an additional challenge. In rural or resource-limited settings, these products may be prohibitively expensive or entirely inaccessible. Vulnerable groups, including pregnant women, infants, and children, are particularly affected, with untreated IDA leading to complications such as preterm birth and developmental delays.

Overcoming these challenges requires targeted policy interventions, expanded healthcare funding, and equitable access to affordable diagnostics and treatments across all population segments.

Key Market Trends

Innovation and Diversification in Treatment Options

Ongoing advancements in IDA treatment have significantly diversified and strengthened the global market. While traditional iron supplements-available in oral, liquid, and intravenous forms-remain central to care, new formulations are improving bioavailability and reducing adverse side effects, thus enhancing patient adherence and outcomes.

Innovative treatments such as erythropoiesis-stimulating agents (ESAs) have transformed the management of moderate to severe anemia. These therapies promote red blood cell production, reducing reliance on blood transfusions and offering a more sustainable, patient-friendly option.

Moreover, targeted therapies are emerging to address specific underlying causes of iron deficiency. For example, patients with gastrointestinal disorders that limit iron absorption now have access to specialized treatments designed to optimize iron uptake and utilization. This personalized approach not only improves treatment efficacy but also expands the market by accommodating the diverse clinical needs of the patient population.

Pharmaceutical firms and healthcare organizations continue to invest in research and innovation, enhancing the overall ecosystem for IDA management. This evolution of therapeutic offerings is broadening the market's reach and solidifying its long-term growth potential.

Key Market Players

• Daiichi Sankyo Company
• Novartis AG
• Rockwell Medical Inc
• Iron4u Aps
• AbbVie Inc
• Sanofi
• Disc Medicine Inc
• Pfizer Inc
• Akebia Therapeutics
• Keros Therapeutics Inc

Report Scope:

In this report, the Global Iron Deficiency Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Iron Deficiency Anemia Market, By Therapy Type:

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion
• Others

Iron Deficiency Anemia Market, By Therapy Areas:

• Obstetrics and Gynecology
• Oncology
• Congestive Heart Failure (CHF)
• Inflammatory Bowel Disease
• Renal
• Others

Iron Deficiency Anemia Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Iron Deficiency Anemia Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Iron Deficiency Anemia Market.

Available Customizations:

Global Iron Deficiency Anemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Iron Deficiency Anemia Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others)
  • 4.2.2. By Therapy Areas (Obstetrics and Gynecology, Oncology, Congestive Heart Failure (CHF), Inflammatory Bowel Disease, Renal, Others)
  • 4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Therapy Type
  • 4.3.2. By Therapy Areas
  • 4.3.3. By End User
  • 4.3.4. By Region

5. Asia Pacific Iron Deficiency Anemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type
  • 5.2.2. By Therapy Areas
  • 5.2.3. By End User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Iron Deficiency Anemia Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Therapy Type
      • 5.3.1.2.2. By Therapy Areas
      • 5.3.1.2.3. By End User
  • 5.3.2. India Iron Deficiency Anemia Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Therapy Type
      • 5.3.2.2.2. By Therapy Areas
      • 5.3.2.2.3. By End User
  • 5.3.3. Australia Iron Deficiency Anemia Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Therapy Type
      • 5.3.3.2.2. By Therapy Areas
      • 5.3.3.2.3. By End User
  • 5.3.4. Japan Iron Deficiency Anemia Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Therapy Type
      • 5.3.4.2.2. By Therapy Areas
      • 5.3.4.2.3. By End User
  • 5.3.5. South Korea Iron Deficiency Anemia Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Therapy Type
      • 5.3.5.2.2. By Therapy Areas
      • 5.3.5.2.3. By End User

6. Europe Iron Deficiency Anemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Therapy Areas
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Iron Deficiency Anemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Therapy Areas
      • 6.3.1.2.3. By End User
  • 6.3.2. Germany Iron Deficiency Anemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Therapy Areas
      • 6.3.2.2.3. By End User
  • 6.3.3. Spain Iron Deficiency Anemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Therapy Areas
      • 6.3.3.2.3. By End User
  • 6.3.4. Italy Iron Deficiency Anemia Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Therapy Type
      • 6.3.4.2.2. By Therapy Areas
      • 6.3.4.2.3. By End User
  • 6.3.5. United Kingdom Iron Deficiency Anemia Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Therapy Type
      • 6.3.5.2.2. By Therapy Areas
      • 6.3.5.2.3. By End User

7. North America Iron Deficiency Anemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Therapy Type
  • 7.2.2. Therapy Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Iron Deficiency Anemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Therapy Areas
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Iron Deficiency Anemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Therapy Areas
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Iron Deficiency Anemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Therapy Areas
      • 7.3.3.2.3. By End User

8. South America Iron Deficiency Anemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Therapy Areas
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Iron Deficiency Anemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Therapy Areas
      • 8.3.1.2.3. By End User
  • 8.3.2. Argentina Iron Deficiency Anemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Therapy Areas
      • 8.3.2.2.3. By End User
  • 8.3.3. Colombia Iron Deficiency Anemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Therapy Areas
      • 8.3.3.2.3. By End User

9. Middle East and Africa Iron Deficiency Anemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Therapy Areas
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Iron Deficiency Anemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Therapy Areas
      • 9.3.1.2.3. By End User
  • 9.3.2. Saudi Arabia Iron Deficiency Anemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Therapy Areas
      • 9.3.2.2.3. By End User
  • 9.3.3. UAE Iron Deficiency Anemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Therapy Areas
      • 9.3.3.2.3. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Iron Deficiency Anemia Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Daiichi Sankyo Company
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Rockwell Medical Inc
• 14.4. Iron4u Aps
• 14.5. AbbVie Inc
• 14.6. Sanofi
• 14.7. Disc Medicine Inc
• 14.8. Pfizer Inc
• 14.9. Akebia Therapeutics
• 14.10.Keros Therapeutics Inc

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료